Syndrome of Early Post Transplantation Improvement

We call this as syndrome of collective signs & symptoms, patient suffer due to ageing & degeneration in general than the primary complaints for which he is given treatment.

MSCs actively interfere with immune tolerance. Mesenchymal Stem cells (MSCs) are known for their properties of

  1. Immunomodulation,
  2. Anti-apoptosis
  3. Angiogenesis
  4. Anti-scarring,
  5. Homing through chemo-attraction
  6. Improving inter cellular electrical signal transduction
  7. Support  growth & differentiation of patient’s own stem and progenitor cells.

The first stage lasts for about one month and is characterized by emergence of early clinical symptoms that develop within a few hours after transplantation stem cells. We have described the early post-transplantation improvement syndrome: improvement in overall health and appetite, diminishing weakness and sweating, restoration of self-care ability, reduction of somatic depression, improvement of emotional status, cognitive abilities, memory and increase in performance, vigor & vitality.

The second stage of cell effect begins within one to two months after transplantation. It is related to reduced clinical manifestations of the disease and is characterized by stabilisation of haemopoesis, improvement of the immunological profile, reduction of inflammatory effects, elevation of Karnofsky index, and improved quality of life.

The improvement is seen as follows—

  • In 65%  cases restoration of work capacity, appetite & sleep is seen.
  • In 50% cases improvement in thinking & mental capacity, disappearance of anxiety, depression, re-vitalization is seen.
  • In 60% cases restoration of immunological parameters is seen.
  • In 80% cases restoration of hematopoiesis, normalization of erythrocyte count & hemoglobin is seen.
  • In 70% cases microcirculation improves, trophic ulcers disappear as well as infectious skin lesions, fungus dermatitis, cutaneus lychenisation & lipoatrophic lesions decrease.

For more Information please visit


Treatment Protocol for Osteoarthritis followed at StemRx

At stemRx we have developed and following the Treatment Protocol for Osteoarthritis. It is briefly explained below.

Mesenchymal stem cells, or MSCs, are multipotent stromal cells that can differentiate into a variety of cell types,including: osteoblasts (bone cells), chondrocytes (cartilage cells), and adipocytes (fat cells).

Mesenchymal stem cells (MSCs) are adult autologous stem cells found in the bone marrow. However, mesenchymal stem cells can also be isolated from other tissues including cord blood, peripheral blood, fallopian tube, and fetal liver and lung. Mesenchymal stem cells are a distinct entity to the mesenchyme, embryonic connective tissue which is derived from the mesoderm and differentiates to form hematopoietic stem cells.Because of their multi-potent capabilities, mesenchymal stem cell (MSC) lineages have been used successfully in animal models to regenerate articular cartilage and in human models to regenerate bone.

Current treatment for cartilage damage in osteoarthritis focuses on surgical interventions such as arthroscopic debridement, microfracture, and cartilage grafting/transplant, total joint replacement. These procedures have complications than hoped, are invasive, and often entail a prolonged recovery time. MSCs can be harvested from the iliac crest through Bone Marrow Aspiration, expanded using the patient’s own growth factors from platelet lysate, then successfully implanted to increase cartilage volume in an adult human knee.

We present a review highlighting the developments in cellular and regenerative medicine in the arena mesenchymal stem cell therapy by successful harvest, expansion, and transplant of autologous mesenchymal stem cells into an adult human knee that repairs the cartilage, ligaments & meniscal damage & lubricate the joint space.

For More information on Osteoarthritis treatment using stem cells visit